Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments

Executive Summary

• Swedish Orphan Biovitrum AB (Sobi) has selected Kinaxis Maestro® to orchestrate its end‑to‑end supply chain for rare‑disease therapies.
• The implementation, led by Deloitte Nordics, will enable real‑time scenario planning, centralized data management and faster response to disruptions across Sobi’s global partner network.
• The announcement highlights Kinaxis’ expanding footprint in the life‑sciences sector and underscores a strategic win with a major biopharmaceutical company serving 40 000 patients in 55 countries.

Key Details

• Customer: Swedish Orphan Biovitrum AB (Sobi), a leading international biopharma focused on hematology, immunology and specialty care.
• Solution: Kinaxis Maestro® platform – AI‑infused supply chain orchestration offering scenario planning, attribute‑based planning, and centralized data visibility.
• Implementation Lead: Deloitte Nordics will manage the rollout of Maestro across Sobi’s partner network.
• Strategic Impact for Sobi: Improves partner connectivity, scales operations, and accelerates response to potential supply disruptions, supporting delivery of critical rare‑disease therapies.
• Quote – Sobi: “Kinaxis is well‑regarded in the life sciences sector… we believe Kinaxis will help us connect better with our partners, respond faster to change and deliver life‑changing treatments.” – Norbert Schoellhorn, VP Global Manufacturing & Supply Chain, Sobi.
• Quote – Kinaxis: “Sobi will utilize Maestro to unlock real‑time collaboration and seamless execution in order to fast‑track the delivery of critical therapies worldwide.” – Fabienne Cetre, EVP EMEA, Kinaxis.
• Broader Context: Kinaxis already serves major life‑sciences firms such as Merck, Novartis, Bristol Myers Squibb, Cardinal Health, Boston Scientific and Servier.

Notable Quotes

• “Kinaxis is well‑regarded in the life sciences sector for its understanding of the unique complexities of supply chains that define this specific industry.” – Norbert Schoellhorn, Sobi.
• “Sobi will utilize Maestro to unlock real‑time collaboration and seamless execution in order to fast‑track the delivery of critical therapies worldwide.” – Fabienne Cetre, Kinaxis.